Medpace Holdings, Inc. (NASDAQ:MEDP) Shares Bought by Bessemer Group Inc.

Bessemer Group Inc. boosted its position in Medpace Holdings, Inc. (NASDAQ:MEDP - Free Report) by 15.0% during the 4th quarter, according to its most recent Form 13F filing with the SEC. The fund owned 576,044 shares of the company's stock after purchasing an additional 75,275 shares during the period. Bessemer Group Inc. owned about 1.85% of Medpace worth $191,379,000 as of its most recent SEC filing.

Several other hedge funds and other institutional investors have also recently made changes to their positions in the business. R Squared Ltd purchased a new stake in Medpace during the fourth quarter valued at approximately $30,000. SBI Securities Co. Ltd. bought a new stake in Medpace during the 4th quarter worth approximately $31,000. Jones Financial Companies Lllp lifted its stake in shares of Medpace by 2,750.0% during the 4th quarter. Jones Financial Companies Lllp now owns 114 shares of the company's stock valued at $38,000 after buying an additional 110 shares in the last quarter. Lindbrook Capital LLC boosted its stake in shares of Medpace by 27.6% in the fourth quarter. Lindbrook Capital LLC now owns 134 shares of the company's stock worth $45,000 after acquiring an additional 29 shares during the period. Finally, Assetmark Inc. raised its position in shares of Medpace by 20.1% during the fourth quarter. Assetmark Inc. now owns 173 shares of the company's stock valued at $57,000 after buying an additional 29 shares during the last quarter. Hedge funds and other institutional investors own 77.98% of the company's stock.

Wall Street Analyst Weigh In

A number of equities research analysts recently commented on the company. Truist Financial decreased their target price on Medpace from $347.00 to $333.00 and set a "hold" rating on the stock in a research report on Thursday. Leerink Partners started coverage on Medpace in a research report on Monday, March 24th. They set a "market perform" rating and a $330.00 price target on the stock. Mizuho lowered their target price on Medpace from $400.00 to $355.00 and set an "outperform" rating for the company in a report on Wednesday, April 9th. Leerink Partnrs raised shares of Medpace to a "hold" rating in a research report on Monday, March 24th. Finally, Robert W. Baird upped their price objective on shares of Medpace from $354.00 to $362.00 and gave the company a "neutral" rating in a report on Monday, January 27th. Ten analysts have rated the stock with a hold rating and four have given a buy rating to the stock. Based on data from MarketBeat.com, the stock currently has a consensus rating of "Hold" and a consensus price target of $357.50.

Medpace Stock Performance

Shares of Medpace stock traded up $4.28 during trading hours on Monday, reaching $302.00. 257,246 shares of the company were exchanged, compared to its average volume of 319,338. The firm has a market cap of $9.13 billion, a PE ratio of 23.91, a PEG ratio of 3.81 and a beta of 1.46. Medpace Holdings, Inc. has a 1 year low of $272.00 and a 1 year high of $459.77. The stock's fifty day moving average is $323.58 and its 200 day moving average is $334.47.

Medpace (NASDAQ:MEDP - Get Free Report) last announced its quarterly earnings data on Monday, February 10th. The company reported $3.67 earnings per share (EPS) for the quarter, beating the consensus estimate of $2.96 by $0.71. Medpace had a return on equity of 51.48% and a net margin of 19.17%. Research analysts expect that Medpace Holdings, Inc. will post 12.29 earnings per share for the current year.

About Medpace

Medpace Holdings, Inc engages in the provision of outsourced clinical development services to the biotechnology, pharmaceutical and medical device industries. Its services include medical department, clinical trial management, data-driven feasibility, study-start-up, clinical monitoring, regulatory affairs, patient recruitment and retention, medical writing, biometrics and data sciences, pharmacovigilance, core laboratory, laboratories, clinics, and quality assurance.